For decades, the path to an Alzheimer’s diagnosis has been a marathon, not a sprint. Patients and families often face months of uncertainty, navigating a complex web of specialist referrals, expensive PET scans, and invasive spinal taps.

In the high-stakes world of clinical research, fixed machine learning models face a silent, inevitable threat: drift. As clinical practices shift, lab equipment is recalibrated, and patient populations evolve, static algorithms slowly degrade in accuracy.

If a patient's kidneys aren't clearing waste efficiently, p-tau217 levels in the blood naturally back up and spike—creating a terrifying "false positive" for Alzheimer’s pathology in patients who are cognitively healthy.

At Glassbury AI, we believe true precision medicine requires algorithms that understand basic biology—including the plumbing.

Focus: Aligning Glassbury AI’s engineering approach with the massive global computational shift and a newly discovered cellular death mechanism.

Focus: Demystifying how Glassbury AI structures data, paired with the industry's shift from symptom-based diagnosis to multi-omic reality.

The biggest breakthrough shaking up the medical community is the arrival of ultra-precise blood-based biomarkers (like the pTau217 test). Scientists can now detect microscopic traces of Alzheimer’s proteins floating right in your bloodstream.

This isn't about AI replacing your doctor; it’s about giving your doctor a massive head start. Catching Alzheimer's risk seven years early opens up a golden window for aggressive lifestyle interventions, personalized therapies, and early-stage clinical trials.

Recent scientific research led by Harvard professor Bruce Yankner suggests that lithium is a vital, naturally occurring element in the brain that plays a critical role in preventing Alzheimer’s disease.

When we think about the fight against Alzheimer’s disease, we often picture a coordinated, unstoppable march toward a cure led by massive organizations like the National Institute on Aging and the Alzheimer's Association. However, the reality of medical research is rarely a straight line. It is a grueling, complex process filled with trial, error, and unexpected pivots.

Alzheimer’s research in the United States is a massive, multi-billion-dollar ecosystem. It is led by a powerful and highly coordinated mix of federal government agencies, non-profit foundations, and elite academic medical centers.

Dementia is a health crisis sweeping the globe. Experts estimate that roughly 50 million people worldwide are currently living with this condition. That enormous figure is expected to nearly double to 80 million by 2030 and potentially surpass 150 million by 2050. Alarmingly, a new dementia diagnosis happens every three seconds.

Malignant brain tumors, including gliomas (like glioblastomas, GBM) and brain metastases (BrM), are among the most difficult cancers to treat, often leading to a challenging prognosis for patients despite the best available therapies—surgery, radiation, and systemic treatments. Researchers are desperately seeking a deeper understanding of the brain tumor microenvironment (TME) to advance biology and improve patient outcomes.

The landscape of Alzheimer’s disease diagnosis and treatment is on the cusp of a dramatic transformation, thanks to the recent US Food and Drug Administration (FDA) clearance of a novel blood-based test developed by Roche. This approval is not just another step in medical technology; it signifies a potential "care paradigm shift" by introducing a simple, accessible tool that can efficiently evaluate the risk of Alzheimer’s disease pathology, particularly in primary care settings. The availability of this "rule-in-rule-out test" is anticipated to drive efficiencies across the entire care continuum for Alzheimer’s disease.

Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's disease, is a devastating neurological condition that progressively attacks the nerve cells responsible for controlling voluntary muscles

In the fast-paced world of medical research, where hope is often measured in small, incremental data points, the detailed reports emerging from clinical trials offer crucial intelligence for the entire scientific community

The world of clinical trials, constantly scrutinizing new therapies for advanced diseases, recently witnessed significant developments in oncology, highlighted by Nanobiotix's radiotherapy-activated cancer drug, JNJ-1900. This drug, previously known as NBTXR3

The fight against Alzheimer’s disease (AD) is entering a new, highly competitive phase, driven by recent scientific breakthroughs and a growing global market. While therapies targeting amyloid proteins have recently been validated, there remains a critical and ongoing unmet need for drugs that utilize alternative mechanisms of action

Dementia, encompassing complex brain disorders like Alzheimer's disease (AD) and related dementias (ADRD), poses an immense global public health challenge. These conditions progressively destroy cognitive abilities—including memory, thinking, and reasoning skills—imposing a tremendous emotional, physical, and financial toll on individuals and their care partners

For many older adults, a simple everyday mishap—like slipping on a wet floor or tripping over a rug—can instantly become a life-altering event. Falls are not just common; they are a significant threat to long-term health, mobility, and independence

The global fight against Human Immunodeficiency Virus (HIV) has reached a critical juncture, marked by the recent European Union (EU) approval of Gilead’s groundbreaking drug, Yeytuo (lenacapavir). This long-acting injectable drug for HIV prevention